Mylan Pharma. Inc v. Warner Chilcott Pub. Ltd. Co.
| Docket Number | 15-2236 |
| Decision Date | 28 September 2016 |
Get this document and AI-powered insights with a free trial of vLex and Vincent AI
Get Started for FreeStart Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial
41 cases
-
In re Loestrin 24 Fe Antitrust Litig.
...States v. Grinnell Corp., 384 U.S. 563, 572, 86 S.Ct. 1698, 16 L.Ed.2d 778 (1966) ); compare Mylan Pharm. Inc. v. Warner Chilcott Pub. Ltd. Co., 838 F.3d 421, 436 (3d Cir. 2016) (" Doryx") (affirming district court decision that relevant market was broad, consisting of all oral tetracycline......
-
Fed. Trade Comm'n v. Abbvie Inc.
...power in the relevant market and that defendants willfully acquired or maintained that power. See Mylan Pharm. Inc. v. Warner Chilcott Pub. Ltd., 838 F.3d 421, 433 (3d Cir. 2016). Here, the FTC asserts that defendants maintained their AndroGel monopoly through the filing of sham litigation ......
-
Premier Comp Solutions LLC v. UPMC
...responsiveness of the demand for one product [X] to changes in the price of a different product [Y]." Mylan Pharms. Inc. v. Warner Chilcott Pub. Ltd. Co. , 838 F.3d 421, 437 (3d Cir. 2016) (citing Queen City Pizza v. Domino's Pizza , 124 F.3d at 438 n.6 ). Where the plaintiff fails to defin......
-
Fed. Trade Comm'n v. Abbvie Inc.
...to dispense a therapeutically equivalent, lower-cost generic drug in place of a brand drug." Mylan Pharm. Inc. v. Warner Chilcott Pub. Ltd. , 838 F.3d 421, 428 (3d Cir. 2016) (internal quotation marks and citations omitted).D. Hypogonadism and testosterone replacement therapies Hypogonadism......
Get Started for Free
3 firm's commentaries
-
FDA Publishes List of Drug Companies Accused of Hindering Generic Entry: Antitrust Implications
...Pharma Ltd. v. Gilead Sciences, Inc., No. 14-3247, 2015 WL 5718398, at *5 (D. Minn. Sept. 29, 2015). 7 Mylan Pharms. Inc. v. Warner Chilcott Pub Ltd. Co., 838 F.3d 421, 435 (3d Cir. 2016). 8 In re Wellbutrin XL Antitrust Litig., 868 F.3d 132, 153 (3d Cir. 2017). 9 Id. at Mark Ford Peter Spa......
-
The Latest Trends in Drug Monopolies
...[18] New York ex rel. Schneiderman v. Actavis PLC (Namenda), 787 F.3d 638 (2d Cir. 2015). [19] Mylan Pharm. Inc. v. Warner Chilcott Pub. Ltd. Co. (Doryx), 838 F.3d 421 (3d Cir. 2016). [20] Id. at 430-31, [21] In re Asacol Antitrust Litig., 233 F. Supp. 3d 247, 267-270 (D. Mass. 2017). [22] ......
-
California's New Reverse Payment Law Departs from Supreme Court Standard in FTC v. Actavis
...824 § 134002(a)(2). 9 AB 824 § 134002(a)(3). 10 Brown Shoe Co. v. United States, 370 US 294, 325 (1962). 11 Mylan Pharm. Inc. v. Warner Chilcott plc, 838 F.3d 421, 433-38 (3d Cir. 2016). 12 AB 824 § 134002(c). The statute purports to forbid the finder of fact from presuming that (1) generic......
20 books & journal articles
-
Making Sense of Monopolization
...Mergers , 5 CRITERION J. ON INNOVATION 29, 35–36, 39–40 (2020). 66 See, e.g. , Mylan Pharms. Inc. v. Warner Chilcott Pub. Ltd. Co., 838 F.3d 421, 438 (3d Cir. 2016) (“Anticompetitive conduct . . . is generally defined as conduct to obtain or maintain monopoly power as a result of competitio......
-
Civil Government Enforcement
...Woodman’s Food Market, Inc. v. Clorox Co., 833 F.3d 743, 749 (7th Cir. 2016). 499. Mylan Pharmaceuticals, Inc. v. Warner-Chilcott PLC, 838 F.3d 421 (3rd Cir. 2016). 748 ANTITRUST LAW DEVELOPMENTS (NINTH) f. COMPETITION AND CONSUMER PROTECTION ADVOCACY AT THE FEDERAL, STATE, AND LOCAL LEVEL ......
-
Monopoly Power
...§ 1” (emphasis added)). 26. Re/Max Int’l v. Realty One, 173 F.3d 995, 1016 (6th Cir. 1999). 27. See Mylan Pharms. Inc. v. Warner/Chilcott, 838 F.3d 421, 434 (3d Cir. 2016) (discussing that direct evidence of monopoly power is “only ‘rarely available’” and claims must be supported by other e......
-
Antitrust Analysis of Pharmaceutical Manufacturer Conduct
...anticompetitive “because [plaintiff’s] generic would not automatically be substituted” for the brand name drug at pharmacies), aff’d , 838 F.3d 421 (3d Cir. 2016); Tricor , 432 F. Supp. 2d at 423 (alleging that brand name drug company’s product changes were anticompetitive because “while [g......
Get Started for Free
